Developer docs
API playgroundTry for free, no card

Search company profiles

eBeam4Therapy

Full company profile

uuid004bcy2

Namestring
eBeam4Therapy
Legal namestring
eBeam4Therapy
Company typeenum
Private
Founded yearint
2022
Descriptiontext

eBeam4Therapy (eB4T) is a European Union-funded research project, established in October 2022 as a consortium between the Weizmann Institute of Science (Rehovot, Israel) and Acceler8 Venture Builder (Mosta, Malta). The project develops laser plasma accelerator (LPA) technology to generate very high energy electrons (VHEE) in the 100-250 MeV range for radiotherapy, with the goal of producing compact, cost-effective radiotherapy equipment that fits into existing treatment rooms without infrastructure modifications and at a fraction of proton therapy cost. The technology uses intense laser pulses to accelerate electrons in a compact plasma medium, replacing the meters-long accelerating structures of conventional RF accelerators.

The project's deliverables cover beam optimization, 3D dosimetric characterization, technical and commercial feasibility demonstration, and go-to-market strategy preparation. Core scientific leadership is provided by Principal Investigator Prof. Dr. Victor Malka, with research staff covering plasma physics, laser diagnostics, beam transport, GEANT4 dose simulations, and optical/dosimetry development. Laboratory facilities were completed at Weizmann in August 2024, equipped with a vacuum chamber and a 50TW Thales laser, enabling first experimental campaigns beginning in April 2025. An emerging application in Stereotactic Arrhythmia Radioablation (STAR) for cardiac arrhythmia was announced in October 2025.

eBeam4Therapy is pre-revenue and structured as a research consortium rather than a commercial entity. Its current funding comes from a European Innovation Council grant under a 3-year project framework, and it has been selected for the EIC Tech-to-Market venture building programme to support investor readiness and commercialization planning. Target end-customers for the future product are radiation oncologists, medical physicists, and hospitals seeking compact radiotherapy solutions, with planned go-to-market through partnerships with medical device companies. The project engages stakeholders via webinars, conferences (ESTRO 2025, LPAW, VHEE23), a quarterly newsletter, and direct outreach to oncologists and radiotherapy professionals.

Short descriptiontext

eBeam4Therapy is a pre-revenue EU-funded research consortium (Weizmann Institute and Acceler8) developing laser plasma accelerator technology to generate very high energy electrons (100-250 MeV) for compact, cost-effective radiotherapy systems targeting hospitals and oncology professionals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRehovot, Israel
HQ citystring
Rehovot
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
laser-plasma accelerators, very high energy electrons, radiotherapy equipment, radiation oncology, VHEE cancer treatment
Industry4 codes
PRIMARYHLAHABAH
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAKAFAC
Radiation Oncology
SECONDARYHLACALAH
Radiation Dose Management & Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAIAGAJ
Radiation Safety, Dosimetry & Regulatory Compliance (Nuclear Medicine)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code2 codes
  • Irradiation Apparatus Manufacturing334517
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Radiation Therapy Equipment
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Not yet commercial
Description

eBeam4Therapy is currently a 3-year EU-funded research project (Phase 1) demonstrating the technological and commercial feasibility of laser-plasma accelerator technology for radiotherapy. Revenue generation is not yet active. The goal is to bring a compact and inexpensive radiotherapy instrument to the market during the next decade.

ebeam4therapy.eu
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

eBeam4Therapy is developing laser-plasma accelerator (LPA) technology to generate very high energy electrons (VHEE) in the 100-250 MeV range for next-generation radiotherapy. The system is designed as a compact, cost-effective radiotherapy instrument that fits existing hospital treatment rooms, offering better tumor targeting with reduced damage to surrounding healthy tissues compared to conventional photon or particle therapy. The 3-year EU-funded project is in the demonstration and pre-validation phase, targeting oncologic radiotherapy and emerging applications such as Stereotactic Arrhythmia Radioablation (STAR).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

eBeam4Therapy (eB4T) is developing a laser plasma accelerator (LPA) technology platform to generate Very High Energy Electrons (VHEE) for radiotherapy applications. The core product consists of the LPA-VHEE system that produces 100-250 MeV electron beams using compact laser technology, offering a paradigm shift in cancer treatment. The platform enables improved tumor targeting with reduced damage to healthy tissues compared to conventional radiotherapy. The technology is being developed as both a standalone radiotherapy solution and for emerging applications in cardiac arrhythmia treatment via STAR (Stereotactic Arrhythmia Radioablation). The project is a 3-year European Union funded initiative led by Weizmann Institute of Science and Acceler8 Venture Builder.

Product and service4 records
1eBeam4Therapy (eB4T) Laser-Plasma Accelerator System
CategoryRadiotherapy Equipment
Description

A next-generation radiotherapy technology using laser plasma accelerator (LPA) technology to generate very high energy electrons (VHEE) in the 100-250 MeV range for cancer treatment. The system is designed to provide compact, cost-effective radiotherapy with improved tumor targeting and reduced damage to healthy tissues compared to conventional photon radiotherapy, targeting hospitals and healthcare facilities.

2LPA-VHEE Radiotherapy Technology
CategoryRadiotherapy Technology Platform
Description

Laser Plasma Accelerator (LPA) technology platform that produces Very High Energy Electrons (VHEE) for radiotherapy applications. Enables routine delivery of highly energetic electrons for treating deep-tissue tumors with sub-millimeter accuracy and percent-level shot-to-shot pointing stability. Developed for radiation oncology researchers and clinical radiotherapy teams.

3VHEE-RT (Very High Energy Electron Radiotherapy)
CategoryRadiotherapy Modality
Description

Radiotherapy modality using very high energy electrons (100-250 MeV) for cancer treatment. Offers better tumor targeting with less damage to adjacent healthy tissues, resilience to organ motion, and compatibility with existing hospital infrastructure. Targeted at hospitals, radiation oncologists, medical physicists, and radiotherapy clinics.

4eB4T LPA-VHEE for STAR (Stereotactic Arrhythmia Radioablation)
CategoryCardiac Radioablation
Description

Emerging clinical application of the eB4T LPA-VHEE system for non-invasive cardiac arrhythmia treatment. Delivers 200 MeV electrons with sub-millimeter accuracy for targeting arrhythmogenic cardiac tissue, offering superior dose distribution and reduced sensitivity to tissue heterogeneities compared to conventional photon-based STAR treatments. Targeted at cardiac electrophysiologists, medical physics teams, and arrhythmia treatment centers.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

One of the world's leading basic research institutions with 250 experimental and theoretical research groups. Houses the Department of Physics of Complex Systems laser facility and the eB4T laboratory. Prof. Victor Malka's research group leads the technical R&D work including laser-plasma accelerator development and VHEE production.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Privately owned venture builder specializing in commercialisation of research-based innovations from ERC, EIC and EIT funded research. Manages the commercial feasibility demonstration, investor requirements, and go-to-market strategy preparation. CEO Antti Heikkila oversees commercial work with 20+ years R&D and commercialisation experience.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Technology transfer company of Weizmann Institute handling IP management and legal aspects for eBeam4Therapy. Led by Adv. Aaron Jaffe with team managing intellectual property protection and commercialization rights.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Prof. Dr. Michael Baumann, Chairman and Scientific Director, provided expert insights on radiotherapy evolution. Prof. Malka addressed the DKFZ Medical Physics Seminar. Ongoing collaboration for market validation and expert feedback.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner with Associate Professor Alessandro Flacco participating as guest speaker at eBeam4Therapy workshop on VHEEs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partner with Researcher Luca Labate participating as guest speaker at eBeam4Therapy workshop, contributing expertise in laser applications.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Medical physics research partner with Medical Physicist Ludovic De Marzi presenting at eBeam4Therapy workshop, providing clinical perspective on radiotherapy applications.

8European STOPSTORM Consortium
Strategic tierMinorTypeStrategic or Co-development Partner
Description

31-institution European consortium advancing Stereotactic Arrhythmia Radioablation (STAR) techniques. eBeam4Therapy's VHEE technology is being positioned as an enabler for next-generation STAR treatment.

ebeam4therapy.eu
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Accuray manufactures CyberKnife and TomoTherapy, both advanced radiotherapy systems designed to deliver highly conformal dose distributions. It is a direct peer competing for the same radiation oncology capex budgets and is known for pushing the boundaries of precision radiotherapy beyond conventional linacs.

TypeEmerging player
Description

ViewRay pioneered MR-guided radiation therapy (MRIdian) with real-time adaptive treatment capability. It represents an emerging modality play focused on improving precision and reducing damage to healthy tissue — the same clinical problem eBeam4Therapy's VHEE approach seeks to address via a fundamentally different physics route.

TypeBroad incumbent
Description

Elekta is a leading manufacturer of linear accelerators (Versa HD, Elekta Unity MR-Linac) and brachytherapy systems, with deep clinical integration across radiation oncology workflows. Its MR-guided Unity platform represents the type of advanced modality eBeam4Therapy competes with for next-generation radiotherapy budgets.

4Ion Beam Applications (IBA)
TypeBroad incumbent
Description

IBA is the world's leading provider of proton therapy systems (ProteusONE, ProteusPLUS) and operates the Dosimetry business unit for beam measurement. As the dominant proton therapy vendor and a dosimetry incumbent, IBA competes for both the particle-therapy modality share and the radiation measurement infrastructure that eBeam4Therapy targets.

TypeOthers
Description

Brainlab develops radiotherapy planning software, ExacTrac image-guided patient positioning, and intraoperative imaging. It is an adjacent technology provider whose software ecosystem eBeam4Therapy's hardware platform would likely integrate with in clinical workflows.

TypeBroad incumbent
Description

Varian, now part of Siemens Healthineers, is the global market leader in conventional radiotherapy linear accelerators (TrueBeam, Edge) and treatment planning software. It is the dominant incumbent whose installed base and clinical relationships eBeam4Therapy's VHEE modality would ultimately have to displace or complement.

TypeEmerging player
Description

RefleXion develops biology-guided radiotherapy (BgRT) that uses PET emissions to target tumors in real time. As an emerging-stage company pursuing a novel precision radiotherapy modality, it is structurally similar to eBeam4Therapy in stage and ambition, though based on a different technological approach.

TypeOthers
Description

RaySearch is a leading independent supplier of treatment planning and oncology information systems (RayStation, RayCare) used across radiotherapy modalities. It is thematically adjacent — eBeam4Therapy will need a treatment planning and dosimetry software ecosystem to be clinically viable, which companies like RaySearch provide.

TypeDirect peer
Description

Mevion develops compact proton therapy systems (MEVION S250-FIT) explicitly designed to address the cost and footprint barriers of conventional proton therapy. It is the closest direct analogue to eBeam4Therapy's value proposition of delivering particle-therapy-quality dose distributions at a fraction of the infrastructure cost.

TypeBroad incumbent
Description

Hitachi's particle therapy division supplies compact proton and carbon-ion therapy systems globally. It is one of the established particle therapy vendors competing for next-generation radiotherapy hospital installations that eBeam4Therapy's compact VHEE platform would target.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

eBeam4Therapy

Radiation Therapy Equipmentebeam4therapy.eu

eBeam4Therapy is a pre-revenue EU-funded research consortium (Weizmann Institute and Acceler8) developing laser plasma accelerator technology to generate very high energy electrons (100-250 MeV) for compact, cost-effective radiotherapy systems targeting hospitals and oncology professionals.

What eBeam4Therapy does

eBeam4Therapy (eB4T) is a European Union-funded research project, established in October 2022 as a consortium between the Weizmann Institute of Science (Rehovot, Israel) and Acceler8 Venture Builder (Mosta, Malta). The project develops laser plasma accelerator (LPA) technology to generate very high energy electrons (VHEE) in the 100-250 MeV range for radiotherapy, with the goal of producing compact, cost-effective radiotherapy equipment that fits into existing treatment rooms without infrastructure modifications and at a fraction of proton therapy cost. The technology uses intense laser pulses to accelerate electrons in a compact plasma medium, replacing the meters-long accelerating structures of conventional RF accelerators.

The project's deliverables cover beam optimization, 3D dosimetric characterization, technical and commercial feasibility demonstration, and go-to-market strategy preparation. Core scientific leadership is provided by Principal Investigator Prof. Dr. Victor Malka, with research staff covering plasma physics, laser diagnostics, beam transport, GEANT4 dose simulations, and optical/dosimetry development. Laboratory facilities were completed at Weizmann in August 2024, equipped with a vacuum chamber and a 50TW Thales laser, enabling first experimental campaigns beginning in April 2025. An emerging application in Stereotactic Arrhythmia Radioablation (STAR) for cardiac arrhythmia was announced in October 2025.

eBeam4Therapy is pre-revenue and structured as a research consortium rather than a commercial entity. Its current funding comes from a European Innovation Council grant under a 3-year project framework, and it has been selected for the EIC Tech-to-Market venture building programme to support investor readiness and commercialization planning. Target end-customers for the future product are radiation oncologists, medical physicists, and hospitals seeking compact radiotherapy solutions, with planned go-to-market through partnerships with medical device companies. The project engages stakeholders via webinars, conferences (ESTRO 2025, LPAW, VHEE23), a quarterly newsletter, and direct outreach to oncologists and radiotherapy professionals.

eBeam4Therapy firmographics

Firmographics
Name
eBeam4Therapy
Legal name
eBeam4Therapy
Website
https://ebeam4therapy.eu
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
eBeam4Therapy is a pre-revenue EU-funded research consortium (Weizmann Institute and Acceler8) developing laser plasma accelerator technology to generate very high energy electrons (100-250 MeV) for compact, cost-effective radiotherapy systems targeting hospitals and oncology professionals.
Ownership category
akta.pro rank

eBeam4Therapy industry classification

Industry
Product category
Radiation Therapy Equipment
NAICS
Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHABAH
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAKAFAC
Radiation Oncology
SECONDARYHLACALAH
Radiation Dose Management & Analytics
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAIAGAJ
Radiation Safety, Dosimetry & Regulatory Compliance (Nuclear Medicine)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Laser-plasma accelerators
  • Very high energy electrons
  • Radiotherapy equipment
  • Radiation oncology
  • VHEE cancer treatment

Where eBeam4Therapy is headquartered

Location

Headquarters

HQ city
Rehovot
HQ country
Israel
HQ region
Middle East

Offices3 records

Markets served

eBeam4Therapy business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Not yet commercial: eBeam4Therapy is currently a 3-year EU-funded research project (Phase 1) demonstrating the technological and commercial feasibility of laser-plasma accelerator technology for radiotherapy. Revenue generation is not yet active. The goal is to bring a compact and inexpensive radiotherapy instrument to the market during the next decade.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

eBeam4Therapy product offering

Product offering

Core offering

eBeam4Therapy is developing laser-plasma accelerator (LPA) technology to generate very high energy electrons (VHEE) in the 100-250 MeV range for next-generation radiotherapy. The system is designed as a compact, cost-effective radiotherapy instrument that fits existing hospital treatment rooms, offering better tumor targeting with reduced damage to surrounding healthy tissues compared to conventional photon or particle therapy. The 3-year EU-funded project is in the demonstration and pre-validation phase, targeting oncologic radiotherapy and emerging applications such as Stereotactic Arrhythmia Radioablation (STAR).

Product overview

eBeam4Therapy (eB4T) is developing a laser plasma accelerator (LPA) technology platform to generate Very High Energy Electrons (VHEE) for radiotherapy applications. The core product consists of the LPA-VHEE system that produces 100-250 MeV electron beams using compact laser technology, offering a paradigm shift in cancer treatment. The platform enables improved tumor targeting with reduced damage to healthy tissues compared to conventional radiotherapy. The technology is being developed as both a standalone radiotherapy solution and for emerging applications in cardiac arrhythmia treatment via STAR (Stereotactic Arrhythmia Radioablation). The project is a 3-year European Union funded initiative led by Weizmann Institute of Science and Acceler8 Venture Builder.

Differentiator

Problem solved

Functional benefit

Products and services

  • eBeam4Therapy (eB4T) Laser-Plasma Accelerator System A next-generation radiotherapy technology using laser plasma accelerator (LPA) technology to generate very high energy electrons (VHEE) in the 100-250 MeV range for cancer treatment. The system is designed to provide compact, cost-effective radiotherapy with improved tumor targeting and reduced damage to healthy tissues compared to conventional photon radiotherapy, targeting hospitals and healthcare facilities.
  • LPA-VHEE Radiotherapy Technology Laser Plasma Accelerator (LPA) technology platform that produces Very High Energy Electrons (VHEE) for radiotherapy applications. Enables routine delivery of highly energetic electrons for treating deep-tissue tumors with sub-millimeter accuracy and percent-level shot-to-shot pointing stability. Developed for radiation oncology researchers and clinical radiotherapy teams.
  • VHEE-RT (Very High Energy Electron Radiotherapy) Radiotherapy modality using very high energy electrons (100-250 MeV) for cancer treatment. Offers better tumor targeting with less damage to adjacent healthy tissues, resilience to organ motion, and compatibility with existing hospital infrastructure. Targeted at hospitals, radiation oncologists, medical physicists, and radiotherapy clinics.
  • eB4T LPA-VHEE for STAR (Stereotactic Arrhythmia Radioablation) Emerging clinical application of the eB4T LPA-VHEE system for non-invasive cardiac arrhythmia treatment. Delivers 200 MeV electrons with sub-millimeter accuracy for targeting arrhythmogenic cardiac tissue, offering superior dose distribution and reduced sensitivity to tissue heterogeneities compared to conventional photon-based STAR treatments. Targeted at cardiac electrophysiologists, medical physics teams, and arrhythmia treatment centers.

Companies that use eBeam4Therapy

Customer profile

Segments4 records

Ideal customer profiles3 records

eBeam4Therapy technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

eBeam4Therapy partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Weizmann Institute of SciencecoreStrategic or Co-development PartnerOne of the world's leading basic research institutions with 250 experimental and theoretical research groups. Houses the Department of Physics of Complex Systems laser facility and the eB4T laboratory. Prof. Victor Malka's research group leads the technical R&D work including laser-plasma accelerator development and VHEE production.
  • Acceler8 Venture BuildercoreStrategic or Co-development PartnerPrivately owned venture builder specializing in commercialisation of research-based innovations from ERC, EIC and EIT funded research. Manages the commercial feasibility demonstration, investor requirements, and go-to-market strategy preparation. CEO Antti Heikkila oversees commercial work with 20+ years R&D and commercialisation experience.
  • Yeda Research & DevelopmentminorImplementation/ SI/ Consulting PartnerTechnology transfer company of Weizmann Institute handling IP management and legal aspects for eBeam4Therapy. Led by Adv. Aaron Jaffe with team managing intellectual property protection and commercialization rights.
  • German Cancer Research Centre (DKFZ)minorStrategic or Co-development PartnerProf. Dr. Michael Baumann, Chairman and Scientific Director, provided expert insights on radiotherapy evolution. Prof. Malka addressed the DKFZ Medical Physics Seminar. Ongoing collaboration for market validation and expert feedback.
  • ENSTAminorStrategic or Co-development PartnerAcademic partner with Associate Professor Alessandro Flacco participating as guest speaker at eBeam4Therapy workshop on VHEEs.
  • Intense Laser Irradiation LaboratoryminorStrategic or Co-development PartnerResearch partner with Researcher Luca Labate participating as guest speaker at eBeam4Therapy workshop, contributing expertise in laser applications.
  • Institut CurieminorStrategic or Co-development PartnerMedical physics research partner with Medical Physicist Ludovic De Marzi presenting at eBeam4Therapy workshop, providing clinical perspective on radiotherapy applications.
  • European STOPSTORM ConsortiumminorStrategic or Co-development Partner31-institution European consortium advancing Stereotactic Arrhythmia Radioablation (STAR) techniques. eBeam4Therapy's VHEE technology is being positioned as an enabler for next-generation STAR treatment.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

eBeam4Therapy competitors and assessment

Company assessment

Direct peers

  • Accuray: Accuray manufactures CyberKnife and TomoTherapy, both advanced radiotherapy systems designed to deliver highly conformal dose distributions. It is a direct peer competing for the same radiation oncology capex budgets and is known for pushing the boundaries of precision radiotherapy beyond conventional linacs.
  • Mevion Medical Systems: Mevion develops compact proton therapy systems (MEVION S250-FIT) explicitly designed to address the cost and footprint barriers of conventional proton therapy. It is the closest direct analogue to eBeam4Therapy's value proposition of delivering particle-therapy-quality dose distributions at a fraction of the infrastructure cost.

Emerging players

  • ViewRay: ViewRay pioneered MR-guided radiation therapy (MRIdian) with real-time adaptive treatment capability. It represents an emerging modality play focused on improving precision and reducing damage to healthy tissue — the same clinical problem eBeam4Therapy's VHEE approach seeks to address via a fundamentally different physics route.
  • RefleXion Medical: RefleXion develops biology-guided radiotherapy (BgRT) that uses PET emissions to target tumors in real time. As an emerging-stage company pursuing a novel precision radiotherapy modality, it is structurally similar to eBeam4Therapy in stage and ambition, though based on a different technological approach.

Broad incumbents

  • Elekta: Elekta is a leading manufacturer of linear accelerators (Versa HD, Elekta Unity MR-Linac) and brachytherapy systems, with deep clinical integration across radiation oncology workflows. Its MR-guided Unity platform represents the type of advanced modality eBeam4Therapy competes with for next-generation radiotherapy budgets.
  • Ion Beam Applications (IBA): IBA is the world's leading provider of proton therapy systems (ProteusONE, ProteusPLUS) and operates the Dosimetry business unit for beam measurement. As the dominant proton therapy vendor and a dosimetry incumbent, IBA competes for both the particle-therapy modality share and the radiation measurement infrastructure that eBeam4Therapy targets.
  • Varian (Siemens Healthineers): Varian, now part of Siemens Healthineers, is the global market leader in conventional radiotherapy linear accelerators (TrueBeam, Edge) and treatment planning software. It is the dominant incumbent whose installed base and clinical relationships eBeam4Therapy's VHEE modality would ultimately have to displace or complement.
  • Hitachi (Proton Therapy): Hitachi's particle therapy division supplies compact proton and carbon-ion therapy systems globally. It is one of the established particle therapy vendors competing for next-generation radiotherapy hospital installations that eBeam4Therapy's compact VHEE platform would target.

Others

  • Brainlab: Brainlab develops radiotherapy planning software, ExacTrac image-guided patient positioning, and intraoperative imaging. It is an adjacent technology provider whose software ecosystem eBeam4Therapy's hardware platform would likely integrate with in clinical workflows.
  • RaySearch Laboratories: RaySearch is a leading independent supplier of treatment planning and oncology information systems (RayStation, RayCare) used across radiotherapy modalities. It is thematically adjacent — eBeam4Therapy will need a treatment planning and dosimetry software ecosystem to be clinically viable, which companies like RaySearch provide.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

eBeam4Therapy social profiles

Digital presence

eBeam4Therapy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

eBeam4Therapy leadership team

Management profile

Number of profiles

Profiles10 records

eBeam4Therapy funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

eBeam4Therapy M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about eBeam4Therapy

What does eBeam4Therapy do?

eBeam4Therapy is developing laser-plasma accelerator (LPA) technology to generate very high energy electrons (VHEE) in the 100-250 MeV range for next-generation radiotherapy. The system is designed as a compact, cost-effective radiotherapy instrument that fits existing hospital treatment rooms, offering better tumor targeting with reduced damage to surrounding healthy tissues compared to conventional photon or particle therapy. The 3-year EU-funded project is in the demonstration and pre-validation phase, targeting oncologic radiotherapy and emerging applications such as Stereotactic Arrhythmia Radioablation (STAR).

Is eBeam4Therapy a public or private company?

eBeam4Therapy is a private company. It is classified as venture growth investor backed and is currently operating.

When was eBeam4Therapy founded?

eBeam4Therapy was founded in 2022. It employs 1 to 10 people.

Where is eBeam4Therapy based?

eBeam4Therapy is headquartered in Rehovot, Israel, in the Middle East region.

How does eBeam4Therapy make money?

One revenue line is on record: not yet commercial.

Who are eBeam4Therapy's main competitors?

Direct peers on record are Accuray and Mevion Medical Systems. Emerging players are ViewRay and RefleXion Medical. Broad incumbents are Elekta, Ion Beam Applications (IBA), Varian (Siemens Healthineers) and Hitachi (Proton Therapy). Others are Brainlab and RaySearch Laboratories.

Does eBeam4Therapy have an API?

No public API is recorded for eBeam4Therapy.

What industry is eBeam4Therapy in?

eBeam4Therapy's product category is Radiation Therapy Equipment. Its primary akta.pro industry code is HLAHABAH, Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim), with a secondary code of HLAKAFAC, Radiation Oncology. Its NAICS code is 334517 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales